JP2024538706A5 - - Google Patents
Info
- Publication number
- JP2024538706A5 JP2024538706A5 JP2024520924A JP2024520924A JP2024538706A5 JP 2024538706 A5 JP2024538706 A5 JP 2024538706A5 JP 2024520924 A JP2024520924 A JP 2024520924A JP 2024520924 A JP2024520924 A JP 2024520924A JP 2024538706 A5 JP2024538706 A5 JP 2024538706A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- monomer
- construct
- terminus
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163253893P | 2021-10-08 | 2021-10-08 | |
| US63/253,893 | 2021-10-08 | ||
| US202263328525P | 2022-04-07 | 2022-04-07 | |
| US63/328,525 | 2022-04-07 | ||
| PCT/US2022/077690 WO2023060188A1 (en) | 2021-10-08 | 2022-10-06 | Activatable cytokine constructs and combination methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024538706A JP2024538706A (ja) | 2024-10-23 |
| JP2024538706A5 true JP2024538706A5 (cg-RX-API-DMAC7.html) | 2025-10-10 |
Family
ID=84272320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520924A Pending JP2024538706A (ja) | 2021-10-08 | 2022-10-06 | 活性化可能サイトカイン構成体及び併用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20230192798A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4412635A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024538706A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240099172A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022360371B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3233707A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL311972A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024004301A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202334185A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023060188A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024353718A1 (en) * | 2023-09-25 | 2026-04-09 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| WO2025195305A1 (en) * | 2024-03-16 | 2025-09-25 | Vibrant Pharma Limited | Multispecific antigen binding proteins and uses thereof |
| CN120932734B (zh) * | 2025-10-13 | 2026-01-30 | 良渚实验室 | 利用中介序列msa与扩散掩码机制的肽序列生成模型及生成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5030719A (en) | 1986-08-28 | 1991-07-09 | Teijin Limited | Cytotoxic antibody conjugates and a process for preparation thereof |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20060024272A1 (en) | 2004-07-29 | 2006-02-02 | Large Scale Biology Corporation | C-terminally truncated interferon |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| US9487590B2 (en) | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| KR20250051130A (ko) | 2013-09-25 | 2025-04-16 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| EP3628328B1 (en) | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| PT3215528T (pt) | 2014-11-06 | 2019-10-11 | Hoffmann La Roche | Variantes da região fc com ligação modificada ao fcrn e métodos de utilização |
| IL300408B2 (en) | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| JP2020528878A (ja) * | 2017-06-20 | 2020-10-01 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | がん治療用インターフェロンプロドラッグ |
| JP2022512124A (ja) | 2018-12-06 | 2022-02-02 | シートムエックス セラピューティクス,インコーポレイテッド | マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法 |
| BR112022009110A2 (pt) * | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| KR20230157448A (ko) * | 2021-03-16 | 2023-11-16 | 싸이톰스 테라퓨틱스, 인크. | 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
-
2022
- 2022-10-06 MX MX2024004301A patent/MX2024004301A/es unknown
- 2022-10-06 CA CA3233707A patent/CA3233707A1/en active Pending
- 2022-10-06 EP EP22809608.7A patent/EP4412635A1/en active Pending
- 2022-10-06 IL IL311972A patent/IL311972A/en unknown
- 2022-10-06 US US17/938,536 patent/US20230192798A1/en not_active Abandoned
- 2022-10-06 JP JP2024520924A patent/JP2024538706A/ja active Pending
- 2022-10-06 AU AU2022360371A patent/AU2022360371B2/en active Active
- 2022-10-06 WO PCT/US2022/077690 patent/WO2023060188A1/en not_active Ceased
- 2022-10-06 KR KR1020247011973A patent/KR20240099172A/ko active Pending
- 2022-10-06 TW TW111138099A patent/TW202334185A/zh unknown
-
2024
- 2024-01-25 US US18/423,006 patent/US20250026801A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ashkenazi et al. | Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. | |
| US12152060B2 (en) | Interleukin-2 variants and methods of uses thereof | |
| JP7682150B2 (ja) | プロテアーゼ活性化治療剤を含む組成物および方法 | |
| JP2024153643A5 (cg-RX-API-DMAC7.html) | ||
| US20220235109A1 (en) | Novel interleukin-2 variants for the treatment of cancer | |
| CN103172746B (zh) | 三聚体Fc融合蛋白及其用途 | |
| AU2002324625B2 (en) | Interleukin-1 receptors in the treatment of diseases | |
| RU2011138951A (ru) | Пропротеины и способы их применения | |
| US9731007B2 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| EA011992B1 (ru) | Гибридный белок антитела l19 к фибронектину ed-b и интерлейкина 12 | |
| JP2003530070A (ja) | Fc融合タンパク質としてのインターフェロン−αタンパク質の発現および搬出 | |
| JP2025169347A (ja) | Fms様チロシンキナーゼ3(flt3)に対するキメラタンパク質およびキメラタンパク質複合体 | |
| KR20030048041A (ko) | 표적-특이적 프로드럭으로서 사용하기 위한항체-사이토카인-사이토카인 억제제로 이루어진 융합단백질(셀렉토카인) | |
| JP2024517871A (ja) | プロテアーゼ活性化治療剤を含む組成物および方法 | |
| RU2007119989A (ru) | Композиции, слитые конструкции и конъюгаты plad домена | |
| JP2024511387A5 (cg-RX-API-DMAC7.html) | ||
| JP2018537093A5 (cg-RX-API-DMAC7.html) | ||
| KR20210084473A (ko) | 항인간 Fn14 항체 | |
| JP2024534062A (ja) | 誘導性サイトカインプロドラッグ及びpd-1/pd-l1併用療法 | |
| JP2024528660A (ja) | リンカーポリペプチド | |
| NZ501831A (en) | Trail binding protein (TRAIL-BP) showing significant homology to the extracellular domains of members of the tumour necrosis factor receptor (TNF-R) and is anchored to cell surface via glycosylphosphatidylinositol (GPI) linkage | |
| CN116113428A (zh) | 白细胞介素-2突变蛋白及其用途 | |
| CA2952902A1 (en) | Anti-il4-il 13 bispecific antibodies | |
| RU2007117716A (ru) | Химерный белок | |
| JP2011507498A5 (cg-RX-API-DMAC7.html) |